Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis

Aún no traducido Aún no traducido
Autores
Categoría Estudio primario
Registro de estudiosClinicalTrials.gov
Año 2014
The purpose of this study is to evaluate efficacy, safety and pharmacokinetics of the vedolizumab (MLN0002) induction and maintenance therapy in Japanese participants with moderate or severe ulcerative colitis (UC).
Epistemonikos ID: 6968dc4a333a42ca5645649e2df773a757c33b84
First added on: Mar 23, 2022